CARL McMILLIAN, PhD
IQ Board of Directors Chair (2018-2020)
IQ Board of Directors Member (2012-Present)
IQ Drug Metabolism Leadership Group Member (2012-2015)
Vice President, Toxicology, Drug Disposition, PKPD, Eli Lilly and Company
PhD, Pharmacy, Medicinal Chemistry, Auburn University
HOW DID YOU FIRST GET INVOLVED IN THE IQ CONSORTIUM?
I had the opportunity to engage with IQ during the formative stage. Contacts and connections formerly established within the framework of the PhRMA technical groups formed the basis of engagement within the Working Group and Leadership Groups of the Translational and ADME Sciences Leadership Group and DruSafe.
WHAT ARE THE BENEFITS OF MEMBERSHIP IN THE IQ CONSORTIUM?
My company benefits from IQ membership and participation in many ways. Some of these include the active engagement in issues and topics impacting drug discovery and development with peer companies in a collaborative framework that operates in a non-competitive or pre-competitive fashion. This framework provides the opportunity for engagement of scientists from within the company that generates broader and deeper perspectives, proposals, responses, etc. It has also proven to be an excellent mechanism for growing and developing talent within the organization.
WHAT IQ ACCOMPLISHMENTS ARE YOU MOST PROUD OF?
I am extremely proud of how IQ has been flexible and responsive to emerging issues and challenges of drug discovery and development. The scientists within the organization enable this through their shared commitment to and passion for developing new medicines.
WHAT COMES NEXT FOR IQ?
IQ is well-poised to rise to the expected and unexpected challenges that will confront pharmaceutical research. The pace and the volume of scientific data generation and insight will continue to increase. IQ is equipped with leaders that can and will be influential and impactful voices in shaping directions of the science and its application to drug development.